As gene therapy sales sputter, one biotech aims to defy the odds

With a strong launch underway for a bladder cancer gene therapy, Ferring is finding the kind of commercial success that’s eluded many of its peers.

Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure

One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the agency’s confrontation with Sarepta.

Inside the growing treatment market for rare diseases

Strand raises another $153M to make ‘programmable’ mRNA drugs

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded to drugs like Keytruda.

Elevidys sales weaken; Neumora gets into obesity

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Autolus says it won’t make money from its cell therapy in Europe until 2027

They said he couldn’t be a pilot with sickle cell. Gene therapy could change that.

Sartorius Stedim Biotech and Nanotein Technologies Partner to Boost Cell Therapy Manufacturing